John G Ullman & Associates Inc. Sells 450 Shares of Encompass Health Corporation $EHC

John G Ullman & Associates Inc. lowered its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 1.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,600 shares of the company’s stock after selling 450 shares during the period. John G Ullman & Associates Inc.’s holdings in Encompass Health were worth $3,507,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EHC. Congress Asset Management Co. bought a new position in shares of Encompass Health in the second quarter worth approximately $92,691,000. Nuveen LLC bought a new position in shares of Encompass Health in the first quarter worth approximately $50,665,000. T. Rowe Price Investment Management Inc. lifted its stake in shares of Encompass Health by 25.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company’s stock worth $210,756,000 after buying an additional 424,691 shares in the last quarter. Strs Ohio bought a new position in shares of Encompass Health in the first quarter worth approximately $34,364,000. Finally, American Century Companies Inc. lifted its stake in shares of Encompass Health by 78.6% in the first quarter. American Century Companies Inc. now owns 723,169 shares of the company’s stock worth $73,243,000 after buying an additional 318,251 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Up 1.3%

Shares of EHC stock opened at $124.55 on Friday. Encompass Health Corporation has a 12 month low of $87.85 and a 12 month high of $127.86. The stock has a market cap of $12.55 billion, a P/E ratio of 24.37, a P/E/G ratio of 2.18 and a beta of 0.93. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.76. The company has a 50 day simple moving average of $123.56 and a two-hundred day simple moving average of $117.26.

Encompass Health (NYSE:EHC) last announced its earnings results on Wednesday, March 16th. The company reported $0.93 EPS for the quarter. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The business had revenue of $136.30 million during the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. On average, research analysts expect that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st were issued a dividend of $0.19 per share. This is an increase from Encompass Health’s previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, October 1st. Encompass Health’s dividend payout ratio is currently 14.87%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on EHC. Truist Financial upped their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Bank of America increased their price objective on shares of Encompass Health from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, September 10th. Weiss Ratings restated a “buy (b+)” rating on shares of Encompass Health in a research report on Wednesday, October 8th. UBS Group increased their price objective on shares of Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, October 2nd. Finally, KeyCorp increased their price objective on shares of Encompass Health from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and a consensus price target of $139.86.

Insider Buying and Selling

In other news, EVP Patrick William Tuer sold 1,020 shares of the stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $123.59, for a total value of $126,061.80. Following the completion of the sale, the executive vice president directly owned 18,846 shares of the company’s stock, valued at $2,329,177.14. This represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 2.00% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.